Wound Center Product Evaluation: A Guide for Value Analysis Committees

Wound Center Product Evaluation: A Guide for Value Analysis Committees

Published 2026-07-07 | Clinical education for wound care physicians, podiatrists, nurses, and wound-center medical directors

Wound Center Product Evaluation: A Guide for Value Analysis Committees

Introduction

Hospital value analysis committees (VACs) evaluating wound biologics face a structurally harder landscape in 2026 than at any point in the prior decade. The Centers for Medicare and Medicaid Services (CMS) replaced the average-sales-price-plus-6% reimbursement model with a single national flat rate of $127.14 per square centimeter for skin substitute products furnished in office and outpatient settings (CMS-1832-F, CY 2026 Physician Fee Schedule Final Rule). At the same time, CMS's Medicare Administrative Contractors (MACs) withdrew the final Local Coverage Determinations (LCDs) for skin substitute grafts and cellular and tissue-based products (CTPs) for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) on December 24, 2025 — meaning no three-tier product classification system was implemented and coverage continues to be evaluated on a case-by-case reasonable-and-necessary basis (CMS Fact Sheet, December 2025).

The net effect for VACs: pricing is flatter and margin is tighter, but the clinical evidence that separates one product from another matters more, not less. A formulary addition approved on unit price alone may produce worse total-episode costs than a higher-priced product with stronger closure data. A product with Level I evidence in one wound type may have no published evidence in another. A vendor with Accreditation Association for Tissue Banks (AATB) accreditation and a documented quality management system reduces institutional risk in ways that a lower-cost entrant without either does not.

This guide provides a structured, vendor-neutral evaluation framework organized across six domains: evidence quality, cost-per-closure modeling, supply chain reliability, reimbursement alignment, vendor credentialing, and post-implementation monitoring. A downloadable one-page checklist (Section 8) distills each domain into actionable questions for committee review.

For a companion framework on financial justification, see the procurement-focused Wound Biologics ROI analysis. For HCPCS code reference and formulary justification templates, see the Wound Biologics Procurement Buyer's Guide.

1. Evidence Quality Hierarchy

The single most important question a VAC should ask about any wound biologic is not "What does it cost?" but "What level of evidence supports its use in the wound type we treat most often?"

The evidence hierarchy in wound care follows a familiar structure, but its application to CTPs requires nuance:

Level I — Randomized Controlled Trials and Meta-Analyses. The strongest evidence comes from prospective RCTs that compare the product plus standard of care (SOC) against SOC alone, with complete wound closure at a defined endpoint (typically 12 weeks) as the primary outcome. A 2024 systematic review and meta-analysis published in The Lancet (PMID 38991578) evaluated skin substitutes in DFU and reported that amniotic membrane products achieved significantly higher complete closure rates versus SOC, with an odds ratio of 2.31 (95% CI 1.52–3.51). Products with at least one published RCT reporting a statistically significant advantage over SOC should receive the highest evidentiary weight in VAC deliberations.

A critical caveat: an RCT demonstrating efficacy for one product in a category does not automatically validate every product in that category. Evidence is product-specific. A dehydrated amniotic membrane allograft from Manufacturer A with published RCT data is not clinically interchangeable with a dehydrated amniotic membrane allograft from Manufacturer B that has only case series data — processing method, sterilization protocol, and donor screening procedures all differ.

Level II — Prospective Cohort Studies. Well-designed prospective cohort studies with predefined endpoints and consecutive enrollment provide the next tier of evidence. These studies lack randomization but can demonstrate real-world effectiveness across broader patient populations than RCTs typically enroll. The key quality markers are: predefined enrollment criteria, complete wound closure as a primary or co-primary endpoint, standardized application protocols, and reporting of adverse events. Level III — Retrospective Case Series. Retrospective case series and single-arm studies provide the lowest tier of admissible evidence for formulary decisions. These studies can illustrate use patterns, patient characteristics, and safety signals but cannot establish comparative effectiveness. A VAC should not rely on case series alone to justify formulary inclusion of a product for which a competing product has Level I evidence in the same indication. Practical weighting for VAC review. For each product under consideration, the committee should request a summary table mapping the available evidence to the target wound types and severity levels treated at the institution. A product with only Level III evidence in DFU should not be weighted equally against a product with Level I evidence in DFU, regardless of price. This is not a clinical judgment — it is a procurement risk assessment. Products backed by weaker evidence carry higher institutional risk of non-coverage determinations, adverse outcomes, and formulary challenge.

2. Cost-Per-Closure Modeling: Total Cost of Care vs Unit Price

Unit price is the most visible cost metric and the least informative. A product priced at $500 per application that achieves closure in four weeks is less expensive to the institution than a product priced at $200 per application that requires twelve weeks of treatment — once clinician time, facility overhead, and the cost of delayed closure are accounted for.

The total cost of care framework. The direct cost of a wound biologic includes the acquisition cost, the application procedure cost (facility time, clinician time, secondary dressings), and any ancillary costs (cold-chain storage, thawing/rehydration protocols, staff training). Indirect costs include the cost of treatment failure — additional clinic visits, hospitalizations, amputations, and readmissions. Nussbaum et al. (Value in Health, 2018) estimated that DFU care costs are 5.4 times higher in the year after the first ulcer episode and 2.8 times higher in the second year compared to baseline. A biologic that reduces time to closure by even two weeks generates savings beyond the product's unit price. Cost-per-closure calculation. A simplified model:

> Cost per closure = (Average number of applications to closure × unit acquisition cost) + (Average number of clinic visits to closure × per-visit facility overhead)

A VAC evaluating two products for DFU formulary inclusion should request per-unit acquisition pricing, average applications-to-closure data (from published evidence), and a per-visit cost estimate for the institution's wound center. The product with the lower cost-per-closure should be preferred, all else equal, even if its unit price is higher. This model is standard in value-based procurement and is recommended by the Wound Healing Society's health economics guidance (Wound Repair Regen, 2016).

For a deeper discussion of ROI modeling, see the Wound Biologics ROI for Value Analysis Committees framework.

3. Supply Chain Reliability

A product that closes wounds faster is irrelevant if it is not on the shelf when the patient is in the treatment room. Supply chain reliability encompasses five sub-domains:

Lead times. Standard lead time from order to delivery, and the vendor's track record against that commitment. A VAC should request 12 months of on-time delivery data for each product under consideration. Backorder history. Frequency, duration, and root cause of backorder events in the prior 24 months. Chronic backorders signal either manufacturing capacity constraints or raw-material supply vulnerability — both of which should be disclosed and evaluated. Cold chain requirements. Cryopreserved products require storage at −60°C to −80°C, ultralow-temperature freezers with continuous temperature monitoring and alarm systems, validated cold-chain shipping from manufacturer to clinic, and staff training on thawing protocols. A facility without existing ultralow-temperature infrastructure must factor capital costs (freezer acquisition, monitoring, calibration, maintenance) into the total cost of adopting cryopreserved products. Dehydrated products stored at ambient temperature (15–30°C) require no cold-chain capital investment. The decision between formats should be driven by wound biology first — but logistics second. For a detailed comparison of format tradeoffs, see the clinical decision guide on dehydrated vs cryopreserved amniotic membrane. Shelf life and inventory management. Dehydrated products typically carry a 2–5 year shelf life at ambient temperature. Cryopreserved products typically carry a 2-year shelf life at specified ultralow temperatures. Longer shelf life reduces waste from expiration and supports bulk purchasing at favorable contract terms. Single-source risk. A VAC should ask: if this vendor's manufacturing facility goes offline for any reason (FDA enforcement action, natural disaster, raw-material shortage), what is the institution's contingency plan? Formulary inclusion of at least two products per wound-type category reduces single-source dependency and preserves clinical continuity.

4. Reimbursement Alignment

The 2026 CMS payment restructuring simplified the coding landscape but did not simplify the coverage landscape. VACs evaluating wound biologics must understand both.

CPT coding. Application of skin substitute grafts is reported with CPT codes 15271–15278 (anatomic site and size-specific). The product itself is not separately coded; it is reimbursed as an incident-to supply at the flat $127.14/cm² rate. Products with a Section 351 FDA Biologics License Application (BLA) remain separately payable under the biologics payment framework, but these represent a small fraction of the wound biologics market. Coverage determinations. Because CMS withdrew the final LCDs that would have implemented a three-tier (Covered / Discretionary / Non-Covered) classification, coverage is currently determined by each MAC under its existing reasonable-and-necessary framework. A product that is routinely covered by one MAC may face additional documentation requirements or denial risk under another MAC. The VAC should verify that products under consideration are routinely covered by the MAC(s) serving the institution's patient population, and should request sample prior-authorization outcomes and denial rates from each vendor. For a comprehensive discussion of MAC-by-MAC coverage variability, see the Medicare Coverage Eligibility Guide. Prior authorization burden. Products requiring prior authorization add administrative overhead: staff time for submission, follow-up, and appeals. The VAC should request the vendor's prior-authorization support resources — some manufacturers provide dedicated reimbursement support teams that handle MAC submissions and appeals on behalf of the institution, which represents a meaningful operational cost offset.

5. Vendor Credentialing

Before evaluating clinical evidence or unit cost, a VAC should verify that the vendor meets baseline regulatory and quality standards. Credentialing is a binary gate: a vendor without the following credentials should not advance to clinical or cost evaluation.

FDA registration and regulatory pathway. Wound biologics derived from human amniotic membrane are regulated under 21 CFR Part 1271 as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Products that meet the criteria in 21 CFR 1271.10(a) — minimally manipulated, intended for homologous use, not combined with another article (except water, crystalloids, or sterilizing/preserving/storage agents), and without systemic effect — are regulated solely under Section 361 of the Public Health Service Act and do not require premarket approval. The establishment must register with FDA and list its HCT/Ps. Products that do not meet all 1271.10(a) criteria are regulated as drugs, devices, or biologics under Section 351 and require a BLA, PMA, or 510(k) clearance.

The VAC should verify each vendor's FDA establishment registration status, the regulatory pathway for each product under consideration (361 HCT/P vs 351 BLA vs 510(k)), and whether the manufacturer has been subject to FDA Warning Letters, Form 483 observations, or enforcement actions in the prior five years.

AATB accreditation. Accreditation by the Association for Advancing Tissue and Biologics (AATB) is the definitive private-sector credential for tissue banking in the United States. The 15th Edition of the AATB Standards for Tissue Banking, effective January 31, 2025, establishes requirements for donor screening and eligibility determination, aseptic processing, quality assurance, labeling, storage, distribution, and adverse event reporting. AATB accreditation requires an on-site inspection by an independent AATB assessment team and is subject to biennial re-inspection. A VAC should not consider a tissue-based product from a manufacturer that is not AATB-accredited — this is the minimum standard for donor-screening and processing quality in the United States. cGMP compliance. FDA's current Good Tissue Practice (cGTP) regulations at 21 CFR 1271, Subpart D, require establishments to maintain a quality program, control environmental conditions and equipment, validate processes, manage supplies and reagents, and investigate and report adverse events. The VAC should request the vendor's quality manual, environmental monitoring data, and adverse-event reporting history. Track record and litigation history. The VAC should verify how long the vendor has been commercially active in wound biologics, how many units of the product under consideration have been applied clinically, and whether the vendor is party to active litigation, DOJ investigations, or CMS audit actions related to its wound care products. A vendor with five years of commercial distribution and an established adverse-event reporting history presents lower institutional risk than a new market entrant with no track record.

6. Post-Implementation Monitoring

Formulary approval is the beginning of product evaluation, not the end. A VAC should establish a post-implementation monitoring protocol before the first unit is applied.

Outcome tracking. Minimum data elements: wound type and severity at baseline, product applied and application count, time to complete closure (or reason for discontinuation), adverse events, and total episode cost. Outcome data should be reviewed at quarterly VAC meetings and compared against the evidence claims that supported the initial approval. Adverse event reporting. The VAC should designate a clinical lead responsible for reporting any product-associated adverse events to the manufacturer and to FDA's MedWatch program. The vendor should provide a summary of adverse-event reports and product complaints on at least a quarterly basis. An unexpected increase in adverse events should trigger an immediate VAC review, not wait for the quarterly cycle. Contract review cadence. Product contracts should be reviewed at least annually. The review should incorporate: updated clinical evidence (new RCTs, meta-analyses, or real-world data that may shift the evidence weighting), pricing changes, and any changes in MAC coverage policies that affect reimbursement. A product approved under favorable evidence in 2026 should not remain on formulary by inertia in 2029 if new evidence favors a competing product.

7. Downloadable Checklist Framework

The following one-page checklist distills each evaluation domain into actionable questions. Committees may adapt this framework to their institutional procurement policies.

| Domain | Key Questions | Required Documentation | |---|---|---| | Evidence Quality | What is the highest level of published evidence (RCT, cohort, case series) supporting this product for the target wound type? | Published studies; evidence table mapping product × wound type × evidence level | | Cost-per-Closure | What is the estimated total cost per closure (acquisition cost × applications + clinic visits × facility overhead)? | Unit pricing; average applications-to-closure data; institutional per-visit cost estimate | | Supply Chain | What is the average lead time, backorder rate (past 24 months), and cold-chain requirement? | 12-month on-time delivery data; backorder history; cold-chain validation records | | Reimbursement | Is this product covered by the relevant MAC(s) under existing reasonable-and-necessary criteria? What is the prior-authorization burden? | MAC coverage verification; sample prior-auth outcomes; denial rate data | | Regulatory | What is the FDA regulatory pathway (361 HCT/P, 351 BLA, 510(k))? Has the manufacturer received FDA Warning Letters or Form 483 observations in the prior 5 years? | FDA establishment registration; regulatory pathway classification; enforcement history | | AATB Accreditation | Is the manufacturer AATB-accredited (Standards for Tissue Banking, 15th Edition)? | AATB accreditation certificate; most recent inspection outcome | | cGMP / Quality System | Does the manufacturer maintain a cGTP-compliant quality program (21 CFR 1271, Subpart D)? | Quality manual; environmental monitoring data; adverse-event reporting procedures | | Track Record | How long has this product been commercially distributed? What is the total clinical utilization volume? Are there active litigation, DOJ, or CMS audit actions? | Commercial history; utilization data; litigation/audit disclosure | | Post-Implementation | Is there a defined protocol for outcome tracking, adverse event reporting, and contract review cadence? | VAC monitoring protocol; designated clinical lead; quarterly review schedule |

8. Conclusion

The 2026 CMS payment restructuring compressed margins across the wound biologics category, but it did not compress the clinical imperative. Wounds that fail to close drive downstream costs — hospitalizations, amputations, readmissions — that dwarf the unit cost of any biologic. A VAC that selects products on unit price alone risks higher total-episode costs and worse patient outcomes.

The framework outlined here is designed to shift committee deliberations from "What does it cost per application?" to "What does it cost to close the wound, and what is the evidence that this product does so?" The six evaluation domains — evidence, cost-per-closure, supply chain, reimbursement, credentialing, and monitoring — are interdependent. A product with Level I evidence but chronic backorders is not a formulary candidate. A product with favorable pricing but no AATB accreditation is not a formulary candidate. The VAC's role is to integrate these domains into a single recommendation, supported by documentation, that stands up to clinical, financial, and regulatory scrutiny.

Disclaimer: Reimbursement policies vary by payer, region, and facility type. Verify current CPT/HCPCS codes and coverage with your local Medicare Administrative Contractor (MAC) or commercial payer. This guide is an educational evaluation framework. It does not endorse any specific product, manufacturer, or pricing strategy. No anti-competitive language is intended or implied. Clinical product selection decisions should be made by qualified wound care providers in consultation with their institution's pharmacy and therapeutics or value analysis committee.